(Q35591215)

9 August 2017

1 reference

title

The role of low-molecular-weight heparins in cardiovascular medicine (English)

1 reference

9 August 2017

Hödl R

1

1 reference

9 August 2017

Klein W

series ordinal

2

1 reference

9 August 2017

publication date

1 October 2003

1 reference

Journal of Clinical Pharmacy and Therapeutics

9 August 2017

published in

1 reference

9 August 2017

volume

28

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

371-378

1 reference

Coronary Plaque Disruption

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Diagnosis and risk stratification in patients with acute coronary syndromes according to ESC guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non--ST- segment elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Dalteparin in combination with abciximab during percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Pathogenic mechanisms in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

Calming the plaque to delay intervention for 24 hours in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0269-4727.2003.00504.X

10.1046/J.0269-4727.2003.00504.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference